NCT03522688 is a Phase 4 clinical trial of Dexmedetomidine in Acute Kidney Injury, sponsored by Asan Medical Center.

Who is sponsoring NCT03522688?

NCT03522688 is sponsored by Asan Medical Center.

What drugs are being tested in NCT03522688?

Interventions in NCT03522688: Dexmedetomidine, Normal saline.

What condition does NCT03522688 study?

NCT03522688 studies Acute Kidney Injury, Liver Diseases.

Is NCT03522688 still recruiting?

NCT03522688 is currently status unknown. Last updated 17 July 2023.

Last reviewed 2023-07-17 · How we verify

NCT03522688

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation

Status unknown Phase 4 Last updated 17 July 2023

What this trial tests

Phase 4 trial testing Dexmedetomidine in Acute Kidney Injury in 214 participants. Status unknown.

Timeline

11 July 2017

Primary endpoint
14 July 2023

7 July 2024

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	214
Start date	11 July 2017
Primary completion	14 July 2023
Estimated completion	7 July 2024
Sites	1 location across South Korea

Drugs / interventions tested

Dexmedetomidine (dexmedetomidine) — full drug profile →
Normal saline

Conditions studied

Acute Kidney Injury — all drugs for Acute Kidney Injury →
Liver Diseases — all drugs for Liver Diseases →

Sponsor

Asan Medical Center

Who can join

Adults 20 to 65, any sex, with Acute Kidney Injury or Liver Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known to have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of dexmedetomidine on the incidence of postoperative acute kidney injury in living donor liver transplantation recipients: a randomized controlled trial.
Kwon HM, Kang SJ, Han SB, Kim JH, et al · · 2024 · cited 7× · PMID 38537086 · DOI 10.1097/js9.0000000000001331
Transplant Trial Watch.
O'Callaghan JM, Knight S, Fallon J. · · 2024 · PMID 39104836 · DOI 10.3389/ti.2024.13457

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07306702 — Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients · Phase 4 · withdrawn
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

NCT07273838 — Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome · Phase 2 · recruiting
NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
NCT07351149 — Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery · recruiting
NCT07215702 — A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kid · Phase 2 · recruiting
NCT06654193 — Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury · Phase 1, PHASE2 · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03522688 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 17 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03522688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing